08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

AlphaVax, Harrisvaccines deal

AlphaVax expanded an exclusive license with Harrisvaccines to include rights to use AlphaVax's RNA particle technology to develop vaccines for all companion animal diseases. Harrisvaccines already have exclusive rights to develop the technology in livestock...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

Liquidia management update

Hired Jonathan Smith as CSO, formerly CSO at AlphaVax Inc. Liquidia Technologies Inc., Research Triangle Park, N.C.   Business: Infectious, Drug delivery   ...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

AlphaVax preclinical data

In a mouse model of melanoma, an alphavirus replicon vector system consisting of virus-like replicon particles (VRP) expressing melanocyte differentiation antigens reduced melanoma tumor burden. VRP expressing tyrosine-related protein 2 ( TRP-2, DCT) were...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

CEA-expressing VRP vaccine: Completed Phase I/II enrollment

AlphaVax completed enrollment of 24 patients in an open-label, dose-escalation, U.S. Phase I/ll trial evaluating the intramuscular vaccine given every 3 weeks for a minimum of 4 immunizations, with additional doses given every 3 months...
07:00 , May 4, 2009 |  BioCentury  |  Product Development

Adjuvant Technologies

Adjuvant Technologies Company Adjuvant technology Alphavax Inc. Alphavirus RNA replicon vectors Antigenics Inc. (NASDAQ:AGEN) QS-21 purified saponin extract BiondVax Pharmaceuticals Ltd. (Tel Aviv:BNDK) Bacterial protein flagellin...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

AlphaVax, Novartis deal

AlphaVax granted Novartis exclusive, worldwide rights to develop and commercialize CMV alphavaccine ( AVX601) to prevent cytomegalovirus (CMV) infection. AlphaVax will receive $20 million up front and is eligible for undisclosed milestones and royalties....
00:56 , Dec 30, 2008 |  BC Extra  |  Company News

Novartis licenses CMV vaccine from AlphaVax

AlphaVax (Research Triangle Park, N.C.) granted Novartis (NYSE:NVS; SWX:NOVN) exclusive, worldwide rights to develop and commercialize a vaccine to prevent cytomegalovirus (CMV) infection. The vaccine, which is in Phase I testing, is based on an...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Clinical News

CMV alphavaccine: Phase I data

Initial data from a double-blind, placebo-controlled, U.S. Phase I trial (AVX601-001) in 40 healthy volunteers showed that AVX601 was safe and well tolerated. Most volunteers developed antibody or T cell responses to all 3 CMV...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

AVX502 influenza alphavaccine: Phase I data

In a double-blind, placebo-controlled, Phase I trial in 216 healthy volunteers, subcutaneous and intramuscular injections of AVX502 were safe and well tolerated. Among 38 subjects with prevaccination influenza antibody titers below levels thought to be...